Jefferies Group reiterated their buy rating on shares of AstraZeneca plc (LON:AZN) in a research report sent to investors on Wednesday morning. Jefferies Group currently has a GBX 5,800 ($75.71) target price on the biopharmaceutical company’s stock.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Several other equities research analysts have also recently weighed in on the company. Societe Generale restated a buy rating and set a GBX 7,000 ($91.37) target price on shares of AstraZeneca plc in a research note on Wednesday, September 14th. Morgan Stanley boosted their target price on AstraZeneca plc from GBX 5,000 ($65.27) to GBX 5,800 ($75.71) and gave the stock an overweight rating in a research note on Friday, August 19th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) target price on AstraZeneca plc and gave the stock a sell rating in a research note on Tuesday, September 6th. JPMorgan Chase & Co. restated a neutral rating and set a GBX 4,900 ($63.96) target price on shares of AstraZeneca plc in a research note on Tuesday, August 23rd. Finally, BNP Paribas restated an outperform rating and set a GBX 5,000 ($65.27) target price on shares of AstraZeneca plc in a research note on Monday, June 27th. Five investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. AstraZeneca plc has an average rating of Hold and an average price target of GBX 4,926.80 ($64.31).

AstraZeneca plc (LON:AZN) opened at 5150.00 on Wednesday. The stock’s market cap is GBX 65.15 billion. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The stock’s 50 day moving average price is GBX 5,021.00 and its 200-day moving average price is GBX 4,351.77.

The company also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were paid a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.